2024
Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians
Wiseman A, Alhamad T, Alloway R, Concepcion B, Cooper M, Formica R, Klein C, Kumar V, Leca N, Shihab F, Taber D, Mulnick S, Bushnell D, Hadi M, Bunnapradist S. Use of LCP-Tacrolimus (LCPT) in Kidney Transplantation: A Delphi Consensus Survey of Expert Clinicians. Annals Of Transplantation 2024, 29: e943498-1-e943498-13. PMID: 38526543, PMCID: PMC10944009, DOI: 10.12659/aot.943498.Peer-Reviewed Original ResearchConceptsLCP-tacrolimusImmediate-release tacrolimusKidney transplantationFirst-line optionKidney transplant recipientsRandomized clinical trialsDe novo settingTacrolimus formulationReview available dataEvidence-based recommendationsTrough levelsOnce-DailyTransplant recipientsClinical decision-makingOptimal doseClinical trialsExpert cliniciansConsensus statementTransplant expertsStrength of evidenceClinical practiceKidneyTacrolimusDe novoDelphi consensus survey
2022
Overall Infectious Complications Related to Belatacept Conversion in Comparison to Tacrolimus in Kidney Transplant Recipients
Marvin JE, Azar MM, Belfield KD, Do V, Formica R, Cohen EA. Overall Infectious Complications Related to Belatacept Conversion in Comparison to Tacrolimus in Kidney Transplant Recipients. Progress In Transplantation 2022, 32: 351-356. PMID: 36039533, DOI: 10.1177/15269248221122894.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsProportion of patientsBelatacept conversionInfectious complicationsTransplant recipientsExact testLong-term infectious complicationsFavorable side effect profileOverall infectious complicationsSide effect profileTime of transplantFisher's exact testT-testStudent's t-testMann-Whitney UInduction immunosuppressionTacrolimus patientsKidney transplantMore patientsPrimary outcomeEffect profileTacrolimusOutcome dataHigh incidenceRetrospective evaluationElevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant
Young C, Papiro T, Greenberg JH. Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant. Pediatric Nephrology 2022, 38: 1-2. PMID: 35982345, PMCID: PMC9388350, DOI: 10.1007/s00467-022-05712-0.Peer-Reviewed Original ResearchConceptsCOVID-19 infectionSupratherapeutic tacrolimus levelsTacrolimus levelsKidney transplantCase reportPediatric kidney transplant recipientsElevated tacrolimus levelsKidney transplant recipientsPotent CYP3A4 inhibitorEmergency use authorizationDrug-drug interactionsPaucity of dataCytochrome P450 systemImmunosuppressant medicationsTransplant recipientsSerum creatininePediatric patientsCalcineurin inhibitorsKidney functionCYP3A4 inhibitorsConcomitant useTacrolimusTherapeutic goalsRitonavirDrug Administration
2020
Treatment of idiopathic orbital myositis with frequent relapses: First case with tacrolimus and review of literature
Zheng Y, Zhang Y, Ding M. Treatment of idiopathic orbital myositis with frequent relapses: First case with tacrolimus and review of literature. Journal Of Neuroimmunology 2020, 346: 577316. PMID: 32668345, DOI: 10.1016/j.jneuroim.2020.577316.Peer-Reviewed Original ResearchIdiopathic orbital myositisOrbital myositisFrequent relapsesDiagnosis of idiopathic orbital myositisPatients refractory to steroidsEnlargement of extraocular musclesRecurrent painful ophthalmoplegiaEfficacy of tacrolimusRefractory to steroidsBrain magnetic resonance imagingMagnetic resonance imagingPainful ophthalmoplegiaSteroid resistanceImmunosuppressive agentsIsolated enlargementExtraocular musclesFollow-upTacrolimusRelapseResonance imagingSymptom controlRelapse preventionMyositisPatientsSymptom recovery
2019
Pharmacotherapy Agents in Lymphedema Treatment: A Systematic Review
Forte AJ, Boczar D, Huayllani MT, Lu X, McLaughlin SA. Pharmacotherapy Agents in Lymphedema Treatment: A Systematic Review. Cureus 2019, 11: e6300. PMID: 31815082, PMCID: PMC6897350, DOI: 10.7759/cureus.6300.Peer-Reviewed Original ResearchPharmacotherapy agentsEligibility criteriaLymphedema treatmentSystematic reviewDouble-blinded clinical studySolid cancer treatmentTopical tacrolimusOral administrationClinical studiesSecondary lymphedemaPrimary lymphedemaCancer treatmentLymphedemaPotential papersTherapyTacrolimusTreatmentLymphedema tissueMajority of publicationsLoss of Subpodocytic Space Predicts Poor Response to Tacrolimus in Steroid-Resistant Calcineurin Inhibitor-Naïve Adult-Onset Primary Focal Segmental Glomerulosclerosis
Agrawal P, Nada R, Ramachandran R, Rayat C, Kumar A, Kohli H. Loss of Subpodocytic Space Predicts Poor Response to Tacrolimus in Steroid-Resistant Calcineurin Inhibitor-Naïve Adult-Onset Primary Focal Segmental Glomerulosclerosis. Indian Journal Of Nephrology 2019, 29: 90-94. PMID: 30983748, PMCID: PMC6440328, DOI: 10.4103/ijn.ijn_422_17.Peer-Reviewed Original ResearchFocal segmental glomerulosclerosisSegmental glomerulosclerosisCause of adult-onset nephrotic syndromePrediction of response to treatmentPrimary focal segmental glomerulosclerosisAdult-onset nephrotic syndromeResponse to tacrolimusTreated with tacrolimusResponse to treatmentDuration of illnessTacrolimus responsePartial responseDiagnostic biopsySubpodocyte spaceRetrospective studyNephrotic syndromeSurrogate markerTacrolimusResponse casesPodocyte phenotypePatientsOlder ageGlomerulosclerosisCompare presenceMigratory phenotype
2018
Autoimmune Enteropathy in an Ulcerative Colitis Patient
Rodriguez NJ, Gupta N, Gibson J. Autoimmune Enteropathy in an Ulcerative Colitis Patient. ACG Case Reports Journal 2018, 5: e78. PMID: 30465008, PMCID: PMC6224868, DOI: 10.14309/crj.2018.78.Peer-Reviewed Case Reports and Technical NotesOstomy outputChronic active ileitisHigh ostomy outputImmune-mediated changesUlcerative colitis patientsSignificant clinical improvementActive ileitisAutoimmune enteropathyIntravenous solumedrolClinical improvementColitis patientsNegative workupTotal colectomyEnd ileostomyChronic enteritisSevere disordersTacrolimusAutoimmuneSolumedrolColectomyCyclosporineEnteroscopyIleostomyEnteropathyIleitisLong-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation
Kim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation. Annals Of Hematology 2018, 98: 237-240. PMID: 30027436, DOI: 10.1007/s00277-018-3427-1.Peer-Reviewed Original ResearchConceptsUnrelated donor allogeneic stem cell transplantationDonor allogeneic stem cell transplantationAllogeneic stem cell transplantationSingle-institution pilot studyHost disease (GVHD) prophylaxisShort-course methotrexateStem cell transplantationDisease prophylaxisCell transplantationPilot studyProphylaxisTacrolimusSirolimusTransplantationMethotrexateGraft
2015
Switching STudy of Kidney TRansplant PAtients with Tremor to LCP‐TacrO (STRATO): an open‐label, multicenter, prospective phase 3b study
Langone A, Steinberg S, Gedaly R, Chan L, Shah T, Sethi K, Nigro V, Morgan J, , Formica R, Barr Y, Brennan D, El‐Amm J, Kozlowski T, Matas A, West‐Thielke P, Kistler K. Switching STudy of Kidney TRansplant PAtients with Tremor to LCP‐TacrO (STRATO): an open‐label, multicenter, prospective phase 3b study. Clinical Transplantation 2015, 29: 796-805. PMID: 26113208, PMCID: PMC4755036, DOI: 10.1111/ctr.12581.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsPhase 3b studyDose reductionKidney transplant patientsPatient Global ImpressionCommon side effectsImmediate-release tacrolimusExtended-release formulationMovement disorder neurologistsFurther dose reductionTransplant recipientsMITT populationStable doseTransplant patientsGlobal ImpressionMarin scaleFahn-TolosaAUC exposureSide effectsPatientsTacrolimusMeaningful improvementsDrug concentrationsSignificant tremorTremorInitial Experience of Dual Maintenance Immunosuppression With Steroid Withdrawal in Vascular Composite Tissue Allotransplantation
Diaz-Siso J, Fischer S, Sisk G, Bueno E, Kueckelhaus M, Talbot S, Carty M, Treister N, Marty F, Milford E, Pomahac B, Tullius S. Initial Experience of Dual Maintenance Immunosuppression With Steroid Withdrawal in Vascular Composite Tissue Allotransplantation. American Journal Of Transplantation 2015, 15: 1421-1431. PMID: 25777324, DOI: 10.1111/ajt.13103.Peer-Reviewed Original ResearchConceptsAcute rejectionVCA recipientsMaintenance immunosuppressionSteroid-resistant acute rejectionLate acute rejectionSolid organ transplantationComposite tissue allotransplantationMaintenance steroidsTopical immunosuppressionCurrent immunosuppressionSteroid withdrawalBolus treatmentOrgan transplantationLow doseImmunosuppressionTissue allotransplantationInitial experienceFurther experienceSteroidsRecipientsTacrolimusPatientsTreatmentMonthsLow levels
2013
Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation
Chakkera HA, Chang Y, Bodner JK, Behmen S, Heilman RL, Reddy KS, Mulligan DC, Moss AA, Khamash H, Katariya N, Hewitt WR, Pitta TL, Frassetto LA. Genetic Differences in Native Americans and Tacrolimus Dosing After Kidney Transplantation. Transplantation Proceedings 2013, 45: 137-141. PMID: 23375287, DOI: 10.1016/j.transproceed.2012.10.023.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedATP Binding Cassette Transporter, Subfamily BATP Binding Cassette Transporter, Subfamily B, Member 1Cohort StudiesFemaleGenetic VariationHumansImmunosuppressive AgentsIndians, North AmericanKidney Failure, ChronicKidney TransplantationMaleMiddle AgedPharmacogeneticsPolymorphism, Single NucleotideTacrolimusTime FactorsConceptsKidney transplant recipientsTrough levelsTacrolimus dosingTransplant recipientsSingle nucleotide polymorphismsDaily tacrolimus doseLower tacrolimus dosesTacrolimus pharmacokinetic parametersTacrolimus trough levelsCaucasian kidney transplant recipientsStable dosesTacrolimus doseKidney transplantationTacrolimus dosesTacrolimus pharmacokineticsMonths posttransplantationOral clearanceTacrolimus clearanceDrug eliminationPharmacokinetic parametersVariant single nucleotide polymorphismsTacrolimusDrug metabolismPharmacokinetic studyLow dosage
2012
The impact of tacrolimus on the immunopathogenesis of staphylococcal enterotoxin-induced systemic inflammatory response syndrome and pneumonia
Tilahun A, Karau M, Clark C, Patel R, Rajagopalan G. The impact of tacrolimus on the immunopathogenesis of staphylococcal enterotoxin-induced systemic inflammatory response syndrome and pneumonia. Microbes And Infection 2012, 14: 528-536. PMID: 22273732, DOI: 10.1016/j.micinf.2012.01.001.Peer-Reviewed Original ResearchConceptsStaphylococcal superantigensT cell activationChemokine levelsCell activationSystemic inflammatory response syndromeDR3 transgenic miceEfficacy of tacrolimusInflammatory response syndromeHuman leukocyte antigenImpact of tacrolimusPotent immunosuppressive agentPost-exposure treatmentT cell proliferationS. aureus strainsSystemic cytokinesGut dysfunctionSerum cytokinesResponse syndromeImmunosuppressive agentsLeukocyte antigenSystemic pathologyTacrolimusLethal pneumoniaPneumoniaTransgenic mice
2010
An automated approach to calculating the daily dose of tacrolimus in electronic health records.
Xu H, Doan S, Birdwell K, Cowan J, Vincz A, Haas D, Basford M, Denny J. An automated approach to calculating the daily dose of tacrolimus in electronic health records. AMIA Joint Summits On Translational Science Proceedings 2010, 2010: 71-5. PMID: 21347153, PMCID: PMC3041548.Peer-Reviewed Original ResearchElectronic health recordsUnstructured clinical dataNatural language processingHealth recordsTime-consuming taskUnstructured formatClinical textLanguage processingAutomated ApproachDaily doseData setsTest casesDetailed drug informationDrug mentionsDaily dosesClinical dataMedication informationClinical researchMedication namesDrug informationInformationTacrolimusMedicationsDoseTask
2008
Novel Immunosuppression: R348, a JAK3- and Syk-Inhibitor Attenuates Acute Cardiac Allograft Rejection
Deuse T, Velotta J, Hoyt G, Govaert J, Taylor V, Masuda E, Herlaar E, Park G, Carroll D, Pelletier M, Robbins R, Schrepfer S. Novel Immunosuppression: R348, a JAK3- and Syk-Inhibitor Attenuates Acute Cardiac Allograft Rejection. Transplantation 2008, 85: 885-892. PMID: 18360272, DOI: 10.1097/tp.0b013e318166acc4.Peer-Reviewed Original ResearchConceptsCombination regimensAllograft survivalAcute cardiac allograft rejectionPrevention of acute rejectionCardiac allograft survivalCardiac allograft rejectionPostoperative day 5Th2 immune responseInflammatory cytokine upregulationAnimals treated with different dosesEnzyme-linked immunosorbent assayEvaluate drug interactionsGraft infiltrationAcute rejectionAllograft rejectionGraft functionInhibition of JAK3Immune cellsPlasma levelsCytokine upregulationTacrolimusDrug interactionsPharmacokinetic dataCellular Th1Treatment period
2007
Effect of Inhaled Tacrolimus on Cellular and Humoral Rejection to Prevent Posttransplant Obliterative Airway Disease
Schrepfer S, Deuse T, Reichenspurner H, Hoffmann J, Haddad M, Fink J, Fischbein M, Robbins R, Pelletier M. Effect of Inhaled Tacrolimus on Cellular and Humoral Rejection to Prevent Posttransplant Obliterative Airway Disease. American Journal Of Transplantation 2007, 7: 1733-1742. PMID: 17532751, DOI: 10.1111/j.1600-6143.2007.01858.x.Peer-Reviewed Original ResearchConceptsObliterative airway diseaseTreatment groupsAirway diseaseSystemic side effectsCellular immune activationOrthotopic tracheal transplantationGraft infiltrationCellular rejectionCellular immunosuppressionHumoral rejectionAllograft rejectionElevated BUNImmune activationTacrolimusAerosol inhalationMononuclear infiltrationSide effectsPOD 8Tracheal transplantationAirway graftsPO animalsHistology of graftsGraftTreatmentPodsIs the Malononitrilamide FK778 Better for the Prevention of Acute or Chronic Rejection?
Deuse T, Schrepfer S, Pelletier M, Fischbein M, Robbins R, Reichenspurner H. Is the Malononitrilamide FK778 Better for the Prevention of Acute or Chronic Rejection? Transplantation Proceedings 2007, 39: 569-572. PMID: 17362784, DOI: 10.1016/j.transproceed.2006.12.020.Peer-Reviewed Original ResearchConceptsObliterative airway diseaseUntreated recipientsLuminal obliterationComplete luminal obliterationEfficacy of FK778Rat cardiac transplantsTracheal luminal obliterationCardiac allograft survivalProlonged graft survivalChronic allograft rejectionAcute heart rejectionMalononitrilamide FK778Mycophenolate mofetilAllograft survivalChronic rejectionCardiac transplantationImmunosuppressive agentsAllograft rejectionGraft survivalFK778Heart rejectionAirway diseaseTacrolimusTracheal transplantationIntense infiltrationFK778 in Experimental Xenotransplantation: A Detailed Analysis of Drug Efficacy
Schrepfer S, Deuse T, Koch-Nolte F, Krieger T, Haddad M, Schäfer H, Pelletier M, Robbins R, Reichenspurner H. FK778 in Experimental Xenotransplantation: A Detailed Analysis of Drug Efficacy. The Journal Of Heart And Lung Transplantation 2007, 26: 70-77. PMID: 17234520, DOI: 10.1016/j.healun.2006.10.013.Peer-Reviewed Original ResearchMeSH KeywordsAlkynesAnimalsAntibodies, Anti-IdiotypicAorta, AbdominalCricetinaeDisease Models, AnimalEndothelium, VascularFlow CytometryGraft RejectionHumansImmunoglobulin GImmunoglobulin MInterleukin-2 Receptor alpha SubunitIsoxazolesMaleNitrilesRatsRats, Inbred BNRats, Inbred LewT-LymphocytesTransplantation, HeterologousTreatment OutcomeConceptsXenograft rejectionCombination regimensHyperacute rejectionMyocyte necrosisAnalysis of drug efficacyEfficacy of FK778Model of hyperacute rejectionXenoantibody productionMonotherapy groupImmunosuppressive treatmentCD25 expressionFK778TacrolimusUntreated ratsXenotransplantation modelAortic xenograftsDose-dependentlyComplement depositionExperimental xenotransplantationSirolimusHumoral responseDrug efficacyXenograft infiltrationXenoreactive IgMRegimens
2006
A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis
Belsito D, Wilson D, Warshaw E, Fowler J, Ehrlich A, Anderson B, Strober B, Willetts J, Rutledge E. A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. Journal Of The American Academy Of Dermatology 2006, 55: 40-46. PMID: 16781290, DOI: 10.1016/j.jaad.2006.03.025.Peer-Reviewed Original ResearchConceptsAllergic contact dermatitisNickel-induced allergic contact dermatitisTacrolimus ointmentAdverse eventsContact dermatitisSymptoms of ACDGlobal assessmentChronic allergic contact dermatitisPhysician global assessmentTacrolimus ointment 0.1Pruritus scoreClinical trialsPruritus reductionDay 8TacrolimusDermatitisInner aspectPatientsOintmentSignsTolerabilityArmSymptomsAgentsTrials
2005
Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation
Firpi R, Zhu H, Morelli G, Abdelmalek M, Soldevila‐Pico C, Machicao V, Cabrera R, Reed A, Liu C, Nelson D. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transplantation 2005, 12: 51-57. PMID: 16382464, DOI: 10.1002/lt.20532.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsSustained virological responseVirological responseTransplant recipientsCombination of cyclosporineInterferon-based therapyCombination of interferonEffect of cyclosporineDose-dependent mannerAnti-viral potentialLiver transplantationHistologic diseaseImmunosuppressive agentsViral clearanceHerpes simplexC virusAntiviral effectCyclosporine inhibitsCyclosporineTherapyViral replicationAntiviral activityTacrolimusInterferonReplicon system
2003
Effects of tacrolimus on ischemia‐reperfusion injury
St. Peter SD, Moss AA, Mulligan DC. Effects of tacrolimus on ischemia‐reperfusion injury. Liver Transplantation 2003, 9: 105-116. PMID: 12548502, DOI: 10.1053/jlts.2003.50020.Peer-Reviewed Original ResearchConceptsEffects of tacrolimusIschemia-reperfusion injuryCellular mechanismsCalcium-activated pathwaysInteractions of tacrolimusFree radical metabolismCornerstone agentEfficacious immunosuppressionInflammatory cascadeOrgan transplantationTacrolimusCytoprotective effectsTissue recoveryClinical literatureDiverse actionsRadical metabolismImmunosuppressionInjuryMitochondrial stabilityStress response proteinsReperfusionIschemiaTransplantationTranscription factorsMicrocirculation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply